No, they are talking about therapies already approved elsewhere (like the U.S.) but were awaiting the standard first mhra assessment national review pathways.
The IRP national applicants left the standard national review and went to the IRP national review.
That reduced the queue in the national review assessment process DCVax-l is in.
It means that any established medicine that applied for MAA to MHRA before Jan 1 but hasn’t been assessed at all yet by MHRA The sentence you copy and pasted is clearly written under the heading “Established Medicines”
News 
Market Data 
Discover 
